WASHINGTON, D.C. (November 5, 2009) — McDermott Will & Emery is pleased to announce that partner Sheila D. Walcoff has been invited to join the Massachusetts Institute of Technology’s Center for Biomedical Innovation Strategy and Policy Council (CBI). Ms. Walcoff’s broad base of experience in advising leading pharmaceutical companies, innovative diagnostic companies, biotechnology firms, policy associations and coalitions on federal regulatory and science policy matters will play a key role in furthering CBI’s objectives.
CBI works to overcome the barriers to the development and implementation of biomedical innovation. As a member of CBI’s Strategy and Policy Council, Ms. Walcoff will join an esteemed array of health policy experts in advising the Center, including Victor Dzau, Chancellor for Health Affairs and President and CEO of Duke University Health System; Janet Woodcock, Deputy Commissioner and Chief Medical Officer at the FDA; and other leaders in industry and academia. Ms. Walcoff is also an advisor for a research program, New Development Paradigms Committee (NEWDIGS), launched by MIT – CBI. NEWDIGS is a public-private partnership that has united key stakeholders from government, academia, and industry to focus on redesigning drug development to meet the growing demand for more and better information about benefits, risks and relative effectiveness, while also improving productivity and efficiency.
Ms. Walcoff, based in McDermott’s Washington, D.C. office, is a member of the Firm’s Health Law Department and Life Sciences Government Strategies Practice Group. Her impressive resume includes serving as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS) and as Associate Commissioner for External Relations at FDA. She also serves on the Secretary’s Advisory Committee on Genetics, Health, and Society at HHS (SACGHS).
McDermott Will & Emery’s Health Law Department is one of the largest and most prestigious health law practices in the world. The Firm’s health law, life sciences and government strategies teams counsel prominent companies in every major sector of the health and life sciences industry on regulatory and business transaction issues.